EPIX

ESSA Pharma Inc. Announces Definitive Agreement to Be Acquired by Xenotherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

时间：2025-07-14 20:00:04 市场： 美股 综合

关联： EPIX XOMA

ESSA Pharma Inc - Shareholders Estimated to Receive $1.91 per Share

时间：2025-07-14 20:00:03 市场： 美股 综合

关联： EPIX XOMA

ESSA Pharma Inc - Agreement Includes $2.5 Mln Termination Fee

时间：2025-07-14 20:00:03 市场： 美股 综合

关联： EPIX XOMA

ESSA Pharma Inc - Terminates Masofaniten Clinical Trials, Exploring Strategic Options

时间：2025-02-11 20:05:52 市场： 美股 综合

关联： EPIX

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

时间：2024-12-17 20:00:05 市场： 美股 综合

关联： EPIX

Tang Capital Management, Llc Reports 9.7% Stake in ESSA Pharma as of Nov 1- SEC Filing

时间：2024-11-09 05:58:26 市场： 美股 综合

关联： EPIX

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

时间：2024-11-01 08:57:49 市场： 美股 综合

关联： EPIX

ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc

时间：2024-09-14 05:20:33 市场： 美股 综合

关联： EPIX

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 Esmo Congress

时间：2024-09-14 05:20:33 市场： 美股 综合

关联： EPIX